Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Assessment of Quitting Versus Using Aspirin Therapy In Patients Treated With Oral Anticoagulation for Atrial Fibrillation or Other Indication With Stabilized Coronary Artery Disease

Next Previous
Trial Profile

Assessment of Quitting Versus Using Aspirin Therapy In Patients Treated With Oral Anticoagulation for Atrial Fibrillation or Other Indication With Stabilized Coronary Artery Disease

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 21 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apixaban (Primary) ; Aspirin (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary)
  • Indications Coronary artery disease; Coronary thrombosis; Stroke
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms AQUATIC

Most Recent Events

  • 16 Jan 2025 Status changed from recruiting to discontinued.
  • 12 Jun 2023 Planned End Date changed from 1 Apr 2024 to 1 May 2028.
  • 12 Jun 2023 Planned primary completion date changed from 1 Apr 2024 to 1 May 2028.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top